SUSoreiia A. Urazgildeeva

Soreiia A. Urazgildeeva

*This is an algorithmically generated author record based on publicly available information.

Soreiia A. Urazgildeeva has a total of 200 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reverse Cascade Genetic Screening for Revealing New Cases of Familial Hypercholesterolemia in Russia: Pilot Project

    by Valentina V. Miroshnikova, Artem D. Izyumchenko, Nataliia N. Smirnova, Natalia B. Kuprienko, Soreiia A. Urazgildeeva, Maria N. Grunina, Svetlana V. Linkova, Kseniia V. Dracheva, Kseniia O. Tanayants, Alina A. Petrik, et al.

    Background: Reverse cascade genetic screening, following initial lipid testing, is an effective strategy for the early diagnosis of familial hypercholesterolemia (FH) and related hereditary dyslipidemias. In this study, we present the results of a pilot project in Russia. Methods: This was a hybrid retrospective–prospective cross-sectional study. Analysis of 1897 lipid screenings of children referred to the main pediatric centers in St. Petersburg, Russia, demonstrated that 60 (3.2%) met the Simon Broome criteria for FH, defined as total cholesterol (TC) ≥6.5 mmol/L or low-density lipoprotein cholesterol (LDL-C) ≥4 mmol/L. All families were invited to undergo genetic testing, regardless of their history, with 35 (58%) families participating in the second stage of the study. Targeted sequencing was performed for children, and Sanger sequencing was performed for variant validation in children and their family members. Results: Sixteen children were shown to have causal variants in dyslipidemia-associated genes, including fourteen (40% of 35 tested children) with hereditary dyslipidemias: twelve FH cases (linked to LDLR and APOB genetic variants), one dysbetalipoproteinemia case (APOE), and one sitosterolemia case (ABCG8). Two children were heterozygous for sitosterolemia variants (one case with ABCG5, one case with ABCG8). Family history of FH or atherosclerotic cardiovascular disease (ASCVD) was reported in only 50% of cases, regardless of whether a causal variant was present. TC and LDL-C were higher in the causal variant-positive subgroup. Receiver operating characteristic curve analysis revealed that LDL-C >4.8 mmol/L acted as a diagnostic indicator of disease causing variant with 84% accuracy, 93% sensitivity, and 73% specificity. Conclusions: Reverse cascade genetic screening following selective lipid testing in children is an effective strategy to reveal new FH and other hereditary dyslipidemia cases, helping to mitigate future ASCVD risks and early mortality.

  • Open Access

    Lipid-Laden M1-like Macrophages of Familial Hypercholesterolemia Patients Are Characterized by Increased Interleukin-1β Secretion and Reduced TMEM176A and TMEM176B Gene Expression

    by Artem Izyumchenko, Tatiana Usenko, Kseniia Dracheva, Kristina Legostaeva, Soreiia Urazgildeeva, Kseniia Tanayants, Maria Grunina, Ekaterina Larionova, Pavel Suchko, Oleg Glotov, et al.

    Familial hypercholesterolemia (FH) is a common hereditary dyslipidemia characterized by high levels of low-density lipoprotein (LDL) cholesterol and a risk of premature atherosclerosis. Previous studies showed that cardiovascular risks persist in FH even after hypolipidemic therapy is started and are linked to a proinflammatory status of circulating monocytes. In the current study we aimed to identify FH-specific gene expression patterns of monocyte-derived M1-like macrophages in response to lipid accumulation. RNAseq was performed for four patient and four control paired samples of M1-like macrophages before and after incubation with oxidized LDL (oxLDL). A validation step was performed in 10 patients and 10 controls using real-time PCR and ELISA. RNAseq data analysis revealed 22 DEGs between FH patients and the control group before and 47 DEGs after incubation with oxLDL. Pathway enrichment analysis suggested dysregulation of inflammatory pathways especially IL-1 and chemokine signaling in response to lipid accumulation in FH M1-like macrophages. Validation experiments demonstrated increased interleukin-1β secretion by lipid-laden M1-like macrophages in FH patients and reduced TMEM176A and TMEM176B gene expression compared to controls. Our results suggest FH M1-like macrophages may be predisposed to an accelerated immune response via interleukin-1β due to reduced TMEM176A/B activity.

  • Genetic architecture of familial hypercholesterolemia: a cohort of St. Petersburg residents

    by V. V. Miroshnikova, A. D. Izyumchenko, M. V. Muzalevskaya, K. V. Legostaeva, M. N. Grunina, K. V. Dracheva, S. A. Urazgildeeva, O. A. Berkovich, E. I. Baranova, O. S. Glotov, et al.

    Aim. To determine the frequency of pathogenic and likely pathogenic variants associated with familial hypercholesterolemia (FH) with assessment of the proportion of polygenic FH according to the 6-SNP genetic risk score (GRS) among patients diagnosed with possible/probable/definite FH in St. Petersburg. Material and methods. This study tested a hybrid targeted panel for gene diagnostics of hereditary dyslipidemias, including an expanded list of genes associated with monogenic dyslipidemias and a number of single-nucleotide variants associated with polygenic hypercholesterolemia and cardiovascular risk. Genetic testing was performed on 125 patients. Results. A total of 26 pathogenic and likely pathogenic variants in the LDLR gene were identified in 38 patients, while 6 variants of uncertain clinical significance in the LDLR gene — in 7 patients, and a pathogenic variant 10580G>A (p.Arg3527G) in the APOB gene — in 6 patients. The highest detection rate of causal genetic variants (66,7%) was observed, as expected, in the subgroup of patients with definite FH. Patients with a high polygenic risk of hypercholesterolemia predominated in the subgroups diagnosed with possible and probable FH. Conclusion. The use of an expanded next-generation sequencing (NGS) panel, including genes for hereditary dyslipidemias, as well as loci for calculating the GRS, may be critical for differential diagnosis, determining the etiology of hypercholesterolemia, and personalizing treatment approaches.


  • Open Access

    Effectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry

    by I Alekseeva, U Chubykina, M Ezhov, A Tyurina, T Kolmakova, N Tmoyan, A Sokolov, T Rozhkova, N Kurochkina, I Sergienko, et al.

    Aim. To study the adequacy and effectiveness of lipid-lowering therapy (LLT) prescribed to patients with heterozygous familial hypercholesterolemia (HeFH), including fixed-dose combinations (FDC) of rosuvastatin with ezetimibe, as well as the frequency of achieving target low-density lipoprotein cholesterol (LDL-C) levels.Material and methods. The clinical and demographic data of 3151 patients with HeFH at high or very high cardiovascular risk from the RENAISSANCE registry were retrospectively analysed. Among the 1612 individuals receiving LLT, 477 patients were treated with a combination of rosuvastatin at various doses and ezetimibe 10 mg daily, either as a free combination or as a FDC.Results. The median age of the patients was 46.0 [32.0; 57.0] years. The median LDL-C level was 6.4 [5.3; 7.8] mmol/L. Although LLT was recommended to all participants, approximately half (49%, n=1539) were not receiving treatment. Among the 1612 patients on LLT, 44% (n=703) received statin monotherapy, and 43% (n=697) were treated with a combination of statins and ezetimibe. Of the 477 patients taking rosuvastatin with ezetimibe, the majority were active adults of working age (35-64 years): 335 (80%) vs 86 (20%), p Conclusion. Among patients with НeFH, the use of a FDC of rosuvastatin and ezetimibe is associated with higher treatment adherence and a greater likelihood of achieving target LDL-С levels.


  • Open Access

    High-densitylipoprotein function in various pathological conditions

    by N. N. Smirnova, N. В. Kuprienko, С. А. Уразгильдеева

    The review considers changes in the structure and function of high-density lipoproteins (HDL), which play an important role in the pathogenesis of a number of chronic diseases that somehow stimulate the development of atherosclerosis. HDL function has been shown to be impaired in a number of genetic and acquired diseases leading to dyslipidemia and associated with increased cardiovascular risk such as familial hypercholesterolemia, obesity, metabolic syndrome, chronic kidney disease, diabetes mellitus, inflammatory and autoimmune diseases.

  • Open Access

    High Density Lipoproteins: Metabolism, Biological Functions and Risk of cardiovascular pathology

    by N. N. Smirnova, N. B. Kuprienko, С. А. Уразгильдеева

    High levels of high-density lipoproteins (HDL) in blood plasma have traditionally been considered an anti-atherogenic factor, but this opinion is not always supported by epidemiological and genetic studies. The functions of lipoproteins are of much greater importance, the main of which is the implementation of the reverse cholesterol transport (RCT) from cells to the liver. The part 1 of the review presents the sequence of passage of cholesterol in HDL, shows the importance of each link in this chain for the development of atherosclerosis; the main methods for determining RCT are given. Changes in the structure and function of HDL, which play the important role in the pathogenesis of a number of chronic diseases that in one way or another stimulate the development of atherosclerosis, are considered in part 2 of the review.

  • Compliance of patients with heterozygous familial hypercholesterolemia: 5-year follow-up of the renaissance registry

    by U.V. Chubykina, M.V. Ezhov, T.A. Rozhkova, B.M. Tamaeva, A.A. Sokolov, A.I. Ershova, A.N. Meshkov, V.I. Mikhailina, A.V. Blokhina, A.S. Limonova, et al.

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить комплаентность пациентов с гетерозиготной семейной гиперхолестеринемией (геСГХС) в течение 5-летнего периода работы регистра РЕНЕССАНС (Регистр пациентов с СГХС и пациентов очень высокого сЕрдечно-Сосудистого риска с недоСтАточной эффективНоСтью, проводимой гиполипидемической терапии). МАТЕРИАЛ И МЕТОДЫ РЕНЕССАНС является открытым, национальным, наблюдательным исследованием и включает больных с СГХС. Проводилась оценка факторов риска атеросклероза, анамнеза сердечно-сосудистых заболеваний (ССЗ), интенсивности гиполипидемической терапии (ГЛТ). Каждому пациенту определены уровни общего холестерина, триглицеридов, холестерина липопротеидов высокой плотности в сыворотке крови. Содержание холестерина липопротеидов низкой плотности (ХС ЛНП) рассчитывали по формуле Фридвальда. РЕЗУЛЬТАТЫ В исследование включено 2317 пациентов с геСГХС, из которых 58% — женщин. При включении в регистр 59% больных относились к категории высокого сердечно-сосудистого риска. Динамический визит проведен у 47% пациентов, период наблюдения составил 24 [11; 42] мес. Больные с динамическим визитом чаще имели определенный диагноз геСГХС и отягощенный наследственный анамнез по ССЗ, были моложе и им в более раннем возрасте диагностировали СГХС (ppp<0,001 для всех). Целевого уровня ХС ЛНП достигли 13% пациентов. Данные симуляционного анализа продемонстрировали, что для адекватного контроля уровня ХС ЛНП, не менее 92,5% больных с геСГХС в регистре должны получать трехкомпонентную ГЛТ со статинами, эзетимибом и ингибиторами PCSK9. ЗАКЛЮЧЕНИЕ 5-летнее наблюдение за участниками регистра РЕНЕССАНС демонстрирует увеличение использования многокомпонентных схем лечения, но недостаточное для адекватного контроля ХС ЛНП.


  • Open Access

    Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion

    by G. P. Arutyunov, S. A. Boytsov, M. I. Voevoda, O. M. Drapkina, V. V. Kukharchuk, A. I. Martynov, M. V. Shestakova, V. S. Gurevich, I. V. Sergienko, A. S. Alieva, et al.

    In opinion the Expert council provides management tactics for patients with hypertriglyceridemia (HTG). It is demonstrated that HTG is a common condition in overweight patients and is an important component of residual risk. HTG creates additional conditions for the progression of atherosclerosis, so the level of triglycerides (TG) is recommended to be measured in patients with a high, very high and extremely high risk level. An indication for the appointment of drugs that reduce the concentration of TG is its level of more than 2,3 mmol/L. Statins are the agents of choice to reduce the risk of cardiovascular disease in high-risk patients with hypercholesterolemia and HTG. Fenofibrate is used to correct HTG, and in case of intolerance to it or when the target level of TG is not reached, omega-3 ethers of polyunsaturated fatty acids in a dose of 2-4 g/day are recommended. In patients with HTG with a TG level >5,6 mmol/L, fenofibrate is the agent of choice.


  • Open Access

    Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS)

    by M. V. Yezhov, S. A. Bliznyuk, N. A. Tmoyan, T. A. Rozhkova, D. V. Duplyakov, V. A. Salchenko, M. A. Kachkovsky, I. I. Shaposhnik, В. В. Генкель, V. S. Gurevich, et al.

    Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС)


  • GENERALIZED LIPODYSTROPHY WITH SEVERE HYPERTRIGLYCERIDEMIA

    by M. Muzalevskaia, S. Urazgildeeva, T. Nekrasova, A. Tregubov, D. Malenkovskaya, V. Gurevich, M. Pyatchenkov, A. Sokolov